EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Amphastar Pharmaceuticals's Enterprise Value is $2,370.3 Mil.
Amphastar Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $145.3 Mil. Therefore, Amphastar Pharmaceuticals's EV-to-FCF for today is 16.31.
The historical rank and industry rank for Amphastar Pharmaceuticals's EV-to-FCF or its related term are showing as below:
AMPH'
s EV-to-FCF Range Over the Past 10 Years
Min: -652.88 Med: 29.96 Max: 4909.4
Current: 16.31
During the past 13 years, the highest EV-to-FCF of Amphastar Pharmaceuticals was 4909.40. The lowest was -652.88. And the median was 29.96.
AMPH's EV-to-FCF is ranked better than 62.23% of 511
companies
in the Drug Manufacturers industry
Industry Median: 21.79
vs AMPH: 16.31
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Amphastar Pharmaceuticals's EV-to-FCF
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals's EV-to-FCF Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's EV-to-FCF falls into.
Amphastar Pharmaceuticals's current Enterprise Value is $2,370.3 Mil.
Amphastar Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $145.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Amphastar Pharmaceuticals's PE Ratio for today is calculated as:
Amphastar Pharmaceuticals's share price for today is $40.83.
Amphastar Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.580.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Amphastar Pharmaceuticals EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Amphastar Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Amphastar Pharmaceuticals (Amphastar Pharmaceuticals) Business Description
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AMPH has been successfully added to your 